62nd ASH Annual Meeting and Exposition: 651. Myeloma: Biology and Pathophysiology, excluding Therapy I

Oral and Poster Abstracts
Oral

apoptosis, multiple myeloma, Diseases, smoldering myeloma, cell regulation, Biological Processes, DNA damage, DNA repair, Technology and Procedures, epigenetics, Plasma Cell Disorders, Lymphoid Malignancies, genomics, Myeloid Malignancies, integrative -omics, NGS, microenvironment, RNA sequencing, pathogenesis, WGS, pathways, signal transduction

Moderators:

Jing Yang, PhD, M.D. Anderson Cancer Center and Annamaria Gulla, MD, Dana Farber Cancer Institute

Disclosures:

No relevant conflicts of interest to declare.

9:00 AM

602

Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Myeloma Precursor Disease

Bénedith Oben^1,2^*, Guy Froyen^1,2^*, Kylee H Maclachlan³^*, Binbin Zheng-Lin, MD MSc³^*, Venkata Yellapantula, PhD³^*, Federico Abascal⁴^*, Daniel A. Leongamornlert, PhD⁴^*, Andriy Derkach, PhD⁵^*, Ellen Geerdens²^*, Benjamin Diamond, MD⁶, Ingrid Arijs^1,7^*, Brigitte Maes²^*, Kimberly Vanhees^1,8^*, Malin Hultcrantz, MD, PhD³, Ahmet Dogan, MD, PhD⁹, Yanming Zhang, MD¹⁰, Aneta Mikulasova¹¹^*, Brian Walker, PhD¹²^*, Gareth Morgan, MD, PhD, FRCP¹³^*, Peter J Campbell, PhD⁴^*, Ola Landgren, MD, PhD^3,14, Jean-Luc Rummens^1,2,8^*, Niccolo Bolli, MD, PhD^15,16^* and Francesco Maura, MD^3,14

¹Hasselt University, Hasselt, Belgium
²Jessa Hospital, Hasselt, Belgium
³Memorial Sloan Kettering Cancer Center, New York, NY
⁴Wellcome Sanger Institute, Hinxton, United Kingdom
⁵Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁷VIB - KU Leuven Center for Cancer Biology, Leuven, Belgium
⁸University Biobank Limburg (UBiLim) and Clinical Biobank Jessa Hospital, Hasselt, Belgium
⁹Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
¹²Indiana University School of Medicine, Bloomington, IN
¹³NYU Langone Health, New York University School of Medicine, New York, NY
¹⁴Weill Cornell Medical College, New York, NY
¹⁵Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
¹⁶Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

9:15 AM

603

The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Titouan Cazaubiel^1,2^*, Laure Buisson¹^*, Sabrina Maheo¹^*, Laura Do Souto Ferreira¹^*, Romain Lannes, PhD¹^*, Aurore Perrot, MD, PhD³^*, Cyrille Hulin, MD²^*, Hervé Avet-Loiseau, MD, PhD¹ and Jill Corre, PharmD, PhD¹^*

¹Unité de Génomique du Myélome, IUCT- Oncopole, Toulouse, France
²Service d'hématologie, Hôpital Haut Lévêque, CHU Bordeaux, Bordeaux, France
³Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

9:30 AM

604

Exploring POU2AF1 (BOB-1) Dependency and Transcription Addiction in Multiple Myeloma

Zuzana Chyra, PhD^1,2,3^*, Mehmet Kemal Samur, PhD⁴^*, Anil Aktas-Samur, PhD⁵^*, Yan Xu, MD⁵^*, Eugenio Morelli, MD⁶, Sophia Adamia, PhD⁷, Woojun D Park⁸^*, Lin Charles, PhD⁹^*, Masood A. Shammas, PhD^10,11^*, Roman Hajek, MD, PhD^2,12, Mariateresa Fulciniti, PhD⁵ and Nikhil C. Munshi, MD¹³

¹University Hospital Ostrava, Department of Haemato-Oncology, Ostrava, Czech Republic
²Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
³Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston
⁴Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Department of Medical Oncology, DANA FARBER CANCER INSTITUTE, Boston, MA
⁷Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁸Department of Molecular and Human Genetics, Baylor College of Medicine, Huston, TX
⁹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
¹⁰VA Boston Healthcare System, Boston, MA
¹¹Dana-Farber Cancer Institute, Boston, MA
¹²Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
¹³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

9:45 AM

605

A Novel in-Vivo Model to Examine Homing of Multiple Myeloma Cells in Postnatal, Inducible, and Reversible Loss of Mature Osteoblasts

Cristina Panaroni, PhD¹, Keertik Fulzele, PhD²^*, Tomoaki Mori³^*, Chukwuamaka Onyewadume³^* and Noopur S. Raje, MD⁴

¹Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Cambridge, MA
²Forma Therapeutics, Inc., Watertown, MA
³Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA
⁴Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA

10:00 AM

606

Atpase Family AAA Domain‑Containing Protein 2 (ATAD2) As a Novel Target in Multiple Myeloma

Lakshmi B. Potluri, MBBS^1,2^*, Srikanth Talluri, PhD^1,2^*, Leutz Buon¹^*, Mehmet K. Samur, PhD¹, Anil Aktas-Samur, PhD¹^*, Jialan Shi, MD, PhD², Chandraditya Chakraborty, PhD¹^*, Subodh Kumar, PhD^1,2^*, Rao Prabhala^1,2, Masood A. Shammas, PhD^1,2^* and Nikhil C. Munshi, MD^1,2,3

¹Dana-Farber Cancer Institute, Boston, MA
²VA Boston Healthcare System, Boston, MA
³Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

10:15 AM

607

Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma

Alexandra M Poos, PhD^1,2,3^*, Nicola Giesen, MD^1,2^*, Calogerina Catalano, PhD^1,2^*, Nagarajan Paramasivam, Ph.D.⁴^*, Daniel Huebschmann, MD PhD^4,5,6,7^*, Lukas John¹^*, Anja Baumann²^*, Jason Hochhaus¹^*, Carsten Mueller-Tidow, MD^1,8^*, Sandra Sauer, MD¹^*, Stefanie Huhn, PhD¹^*, Matthias Schlesner, PhD⁹^*, Benedikt Brors, PhD^7,8,10^*, Hartmut Goldschmidt, MD^1,8, Marc S. Raab, MD^1,2^* and Niels Weinhold, PhD^1,2^*

¹Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
²Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
³Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany
⁴Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany
⁵Department of Pediatric Immunology, Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
⁶Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH (HI-STEM), Heidelberg, Germany
⁷Core Center Heidelberg, German Cancer Consortium (DKTK), Heidelberg, Germany
⁸National Center for Tumor Diseases (NCT), Heidelberg, Germany
⁹Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany
¹⁰Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651A.O2.6 651. Myeloma: Biology and Pathophysiology, excluding Therapy I